{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:24:35Z","timestamp":1778844275867,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.4065\/81.9.1225","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"1225-1231","source":"Crossref","is-referenced-by-count":14,"title":["The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?"],"prefix":"10.4065","volume":"81","author":[{"given":"Terry A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.9.1225_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.4065\/81.9.1225_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.4065\/81.9.1225_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00149831-200308000-00004","volume":"10","author":"De Backer","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehab"},{"key":"10.4065\/81.9.1225_bib4","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.9.1225_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.4065\/81.9.1225_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]","volume":"366","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/81.9.1225_bib7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.clinthera.2004.09.005","article-title":"Rosuvastatin in the management of hyperlipidemia","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.4065\/81.9.1225_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354:778]","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1225_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.4065\/81.9.1225_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1225_bib11","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [published correction appears in JAMA. 2005;294:3092]","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.4065\/81.9.1225_bib12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.4065\/81.9.1225_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.9.1225_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"key":"10.4065\/81.9.1225_bib15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.4065\/81.9.1225_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14740338.2.3.269","article-title":"Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era","volume":"2","author":"Jacobson","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"10.4065\/81.9.1225_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1225_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"issue":"suppl 2","key":"10.4065\/81.9.1225_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia: safety and regulatory considerations","volume":"90","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.4065\/81.9.1225_bib20","doi-asserted-by":"crossref","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","article-title":"Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"87","author":"McTaggart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1225_bib21","series-title":"Coumadin tablets\/Coumadin for injection (warfarin sodium) [prescribing information]","year":"2005"},{"key":"10.4065\/81.9.1225_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis [letter]","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1225_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.4065\/81.9.1225_bib24","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1001\/archinte.1996.00440170097011","article-title":"Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study","volume":"156","author":"Pedersen","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1225_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1225_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjcard.2004.06.049","article-title":"Safety of rosuvastatin","volume":"94","author":"Shepherd","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1225_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(99)00294-4","article-title":"Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels","volume":"149","author":"Bakker-Arkema","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.4065\/81.9.1225_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial","volume":"320","author":"Iso","year":"1989","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1225_bib29","author":"Department of Health and Human Services, Food and Drug Administration"},{"key":"10.4065\/81.9.1225_bib30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? the safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy [published correction appears in J Am Coll Cardiol. 2006;47:472]","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.4065\/81.9.1225_bib31","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1225_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1368-5031.2004.00188.x","article-title":"Improving lipid management\u2014to titrate, combine or switch","volume":"58","author":"Schuster","year":"2004","journal-title":"Int J Clin Pract"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T14:03:45Z","timestamp":1558101825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611612342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0025619611612342"],"URL":"https:\/\/doi.org\/10.4065\/81.9.1225","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}